Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.59 |
| ▸ | USP7 | Q93009 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.58 |
| ▸ | NOS2 | P35228 | 8/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26058514 | 1.00 | MBOAT4 (0.59) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022573 | 1.00 | MBOAT4 (0.59) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022534 | 0.94 | MBOAT4 (0.57) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL23098218 | 0.94 | MBOAT4 (0.59) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022594 | 0.93 | MBOAT4 (0.58) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022529 | 0.93 | MBOAT4 (0.58) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL26058696 | 0.92 | MBOAT4 (0.57) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL26058610 | 0.91 | MBOAT4 (0.58) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL22875562 | 0.90 | MBOAT4 (0.71) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL20750769 | 0.90 | MBOAT4 (0.71) | MBOAT4NFE2L2USP7USP2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584775-B2 | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses | REATA PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20190153022-A1 | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES | REATA PHARMACEUTICALS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153022-A1 | C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER USES | IL17A, IL23R, ALOX15 | MBOAT4 1187/4885NFE2L2 415/4885USP7 707/4885 |
| US-11584775-B2 | C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses | IL17A, IL23R, ALOX15 | MBOAT4 1187/4885NFE2L2 415/4885USP7 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.